Costs and length of stay of drug-related hospital admissions in cancer patients

Clin Ther. 2014 Apr 1;36(4):588-92. doi: 10.1016/j.clinthera.2014.02.014. Epub 2014 Mar 14.

Abstract

Background: Most previous studies of the incidence and economic impact of drug-related hospital admissions were not cancer specific, despite the fact that drug-related problems (DRPs) are of particular concern in oncology.

Objective: The goals of this study were to assess the economic impact, particularly the length of stay (LOS) and direct medical costs (DMC), of drug-related hospital admissions and the associated factors in cancer patients in Singapore.

Methods: A prospective study was conducted over a 5-month period in 2 oncology wards at the largest acute tertiary hospital in Singapore. Drug-related admissions were identified from all oncology admissions to these wards, and the demographic, clinical, and cost data of these drug-related admissions were collected. The association between LOS and DMC as well as their associations with age, severity, and preventability of DRPs were examined. A nationwide estimation was made to determine the overall DMC of drug-related hospital admissions among cancer patients.

Results: A total of 151 drug-related admissions that occurred among 137 cancer patients were identified. The mean DMC (in Singapore dollars [SGD]) and LOS per drug-related admission were SGD $4747 and 6.1 days, respectively. A nationwide extrapolation estimated an annual total DMC of SGD $16.2 million. Longer LOS was found to be correlated with higher DMC (rs = 0.86, P < 0.001) and preventable DRPs (P = 0.02).

Conclusions: Drug-related hospitalization among cancer patients is costly; therefore, more attention is warranted to develop and improve strategies for preventing drug-related morbidity and mortality in cancer patients.

Keywords: cancer; costs; drug-related hospital admissions; length of stay.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cancer Care Facilities
  • Costs and Cost Analysis
  • Direct Service Costs*
  • Drug-Related Side Effects and Adverse Reactions / economics*
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Female
  • Hospitalization / economics
  • Humans
  • Incidence
  • Length of Stay / economics*
  • Length of Stay / statistics & numerical data
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Neoplasms / economics
  • Prospective Studies
  • Singapore